A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2004
12/09/2004	US20040248919 Insulin sensitizers which do not increase triglyceride levels or suppress thyroid hormone axis; such as 7-[3,5-di-tert-butyl-2-(2,2-difluoroethoxy)-phenyl]-4-fluoro-3-methyl-octa-2,4,6-trienoic acid; synthesis; retinoid X receptor (rxr)
12/09/2004	US20040248913 (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators
12/09/2004	US20040248912 4- (4-trans-hydroxycyclohexyl)amino-2-phenyl-7H-pyrrolo [2,3D] pyrimidine hydrogen mesylate, its polymorphic forms, and methods for making same
12/09/2004	US20040248909 Adenosine a1 receptor antagonist for treating hypoxia-induced learning memory impairment
12/09/2004	US20040248898 Group V and/or X secretory phospholipase A2 inhibition; suppressing degeneration of serum lipoproteins
12/09/2004	US20040248897 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions
12/09/2004	US20040248889 Analgesics; synthesis
12/09/2004	US20040248886 Neuronal disorders, autoimmune diseases, cancer, cardiovascular diseases; such as 4-Chloro-N-{5-[1-(4-trifluoromethyl-benzyl)-piperidin-3-ylsulfamoyl]-25 thiophen-2-ylmethyl)-benzamide
12/09/2004	US20040248885 Use of thiazole derivatives for preparing a medicine for protecting mitochondria
12/09/2004	US20040248883 Novel heteroaryl derivatives, their preparation and use
12/09/2004	US20040248868 Antiischemic agents; prevent damage to tissues, organs
12/09/2004	US20040248859 Medicinal compositions for treating secondary parathyroid hyperfunction and remedies for cardiovascular complications in association with treatment for secondary parathyroid hyperfunction
12/09/2004	US20040248849 3-Aryl-A-oxy substituted propanoic acids and a process for their preparation
12/09/2004	US20040248848 Use of specific dose of fondaparinux sodium for the treatment of acs
12/09/2004	US20040248820 Administering 2-phthalimidoglutaric acid; vision defects; antitumor agents; anticancer agents
12/09/2004	US20040248817 Therapy for cardiovascular disorders; hypotensive agents; congestive heart failure
12/09/2004	US20040248796 VEGF-B and PDGF modulation of stem cells
12/09/2004	US20040248788 preventing or delaying the onset by administration of growth hormone to a mammal predisposed to essential or primary hypertension; such as when subjected to intrauterine undernutrution
12/09/2004	US20040248771 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
12/09/2004	US20040248767 Modulating serum amyloid a interaction with tanis and agents useful for same
12/09/2004	US20040248763 Canine cardiac diet
12/09/2004	US20040248321 Membrane protein for use in treatment and prevention of inflammatory, circulatory, cell proliferative, metabolic and immunological disorders
12/09/2004	US20040248252 Nucleotide sequences coding mammalian histamine H4 receptor protein for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders
12/09/2004	US20040248251 Receptors and membrane associated proteins
12/09/2004	US20040248249 Protein for use in treatment, prevention and diagnosis of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders
12/09/2004	US20040248240 Nucleotide sequences coding membrane protein for use in identifying modulator for treatment of pain management, epilepsy, stroke, ischemia and heart disease
12/09/2004	US20040248233 Using propyl hydroxylase expression system to identify modulators which interfere with or prevent generation of hypoxic states; screening modulator for treatment and prevention of cell proliferative and thrombotic disorder
12/09/2004	US20040248208 Screening method
12/09/2004	US20040248188 Methods for using tetanus toxin for benificial purposes in animals (mammals)
12/09/2004	US20040248178 Nucleotide sequences coding neuronal outgrowth and stability protein for use in treating ovarian, renal, neurological, cell proliferative and cardiovascular disorders
12/09/2004	US20040248173 Nucleotide sequences coding cyclic peptide receptor for use in identifying modulators for treatment of pituitary hormone, epinephrine release, gastrointestinal, cardiovascular, electrolyte balance, hypertensive, diabetic and respiratory system disorder
12/09/2004	US20040247711 Process for the production of allicin
12/09/2004	US20040247703 Composition for inhibiting glutamate-mediated neurotoxicity comprising ginsenoside Rg3 or ginsenoside Rh2
12/09/2004	US20040247693 Modifying the fatty acid composition of cell membranes of organs and tissues
12/09/2004	US20040247658 Delivery system with increased bioavailability
12/09/2004	US20040247603 Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
12/09/2004	US20040247597 Method of treating atherosclerosis and other inflammatory diseases
12/09/2004	US20040247564 Treating a tissue disorder involving a loss and/or apoptosis of cells by administering an agent that induces phosphorylation and/or activation of protein kinase B to cause proliferation; particularly administering a human stromal-derived factor-1 and a G-CSF to cause proliferation of cardiomyocytes
12/09/2004	CA2527731A1 Substituted pyrrole derivatives as hmg-coa reductase inhibitors
12/09/2004	CA2527483A1 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
12/09/2004	CA2527190A1 Combination of acetylsalicylic acid and alpha-glucosidase inhibitors
12/09/2004	CA2527159A1 3-aminomethyl-pyrrolidines as n-type calcium channel blockers
12/09/2004	CA2514121A1 Composition possessing autonomic nerve function regulating action and use thereof
12/08/2004	EP1484339A2 Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
12/08/2004	EP1484327A1 Nitrogenous heterocyclic compound and medicine thereof
12/08/2004	EP1484320A1 Jnk inhibitor
12/08/2004	EP1484316A1 Novel propionic acid derivative
12/08/2004	EP1484313A1 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
12/08/2004	EP1484061A1 Drugs containing riboflavin-type compounds
12/08/2004	EP1484055A1 Delivery system with increased bioavailability
12/08/2004	EP1483588A2 Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders
12/08/2004	EP1483297A2 Antibodies derived from anti ed-b l19 and targeting tumor vasculature
12/08/2004	EP1483289A2 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
12/08/2004	EP1483285A1 INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME
12/08/2004	EP1483284A2 Selective dipeptide inhibitors of kallikrein
12/08/2004	EP1483271A1 Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
12/08/2004	EP1483270A1 Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
12/08/2004	EP1483269A1 Racemization and enantiomer separation of clopidogrel
12/08/2004	EP1483266A1 Spiro compounds with npy antagonistic activity
12/08/2004	EP1483263A1 Thiazolyl urea compounds for the treatment of cancer
12/08/2004	EP1483261A1 Phthalimide carboxylic acid derivatives
12/08/2004	EP1483260A1 Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
12/08/2004	EP1483257A1 Quinazoline compounds useful in therapy
12/08/2004	EP1483247A2 Aryl substituted pyrimidines and the use thereof
12/08/2004	EP1483244A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase
12/08/2004	EP1483242A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies
12/08/2004	EP1483240A1 Indolamid derivatives which possess glycogen phosphorylase inhibitory activity
12/08/2004	EP1483239A2 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
12/08/2004	EP1483236A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists
12/08/2004	EP1483232A1 Salts of nateglinide
12/08/2004	EP1483231A1 Novel cinnamate salts, method for production and use thereof as medicaments
12/08/2004	EP1482988A1 METHOD OF RADIO−LABELLING BIOMOLECULES
12/08/2004	EP1482973A1 Methods of modulating cd200 receptors
12/08/2004	EP1482962A2 Method of treating trx mediated diseases
12/08/2004	EP1482954A2 Alpha-substituted arylalkyl phosphonate derivatives
12/08/2004	EP1482953A1 Alpha-substituted heteroarylalkyl phosphonate derivattives
12/08/2004	EP1482941A1 Beta-sheet mimetics and composition and methods relating thereto
12/08/2004	EP1482940A2 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
12/08/2004	EP1482937A2 Novel tyloindicines and related processes, pharmaceutical compositions and methods
12/08/2004	EP1482935A1 Thiazole and oxazole derivatives which modulate ppar activity
12/08/2004	EP1482934A1 2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases
12/08/2004	EP1482932A1 N3 alkylated benzimidazole derivatives as mek inhibitors
12/08/2004	EP1482931A2 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/08/2004	EP1482926A2 Amino-methyl substituted tetracycline compounds
12/08/2004	EP1482922A1 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
12/08/2004	EP1482896A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
12/08/2004	EP1482895A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
12/08/2004	EP1482858A2 Methods for aneurysm repair
12/08/2004	EP1482795A1 New immunoeffector compounds
12/08/2004	EP1482787A2 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
12/08/2004	EP1436283A4 Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
12/08/2004	EP1434886A4 Mid 241 receptor, a novel g-protein coupled receptor
12/08/2004	EP1385850B1 New process for the preparation of oxabispidines
12/08/2004	EP1381363B1 Imidazo [1,2-a]-pyridine derivatives as mglur5 antagonists
12/08/2004	EP1363898A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
12/08/2004	EP1341754B1 Substituted anthranilic acids
12/08/2004	EP1339403B1 Repinotan kit
12/08/2004	EP1220856B1 Pyrazolo[4,3-d]pyrimidine derivatives
12/08/2004	EP1149102B1 Triazolo-pyridazine derivatives as ligands for gaba receptors
12/08/2004	EP1141014B1 Insulin-like growth factor (igf) i mutant variant

1 ... 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 ... 1595